Tagged with Healthcare,

Healthcare Orange Healthcare CEO Elie Lobel discusses the importance of digitalization to the healthcare industry, major challenges, and the tremendous work that has already been done in the e-health regulatory field both in France and internationally. Could you give us a brief introduction to Orange Healthcare? What are the milestones and achievements…

PPP Known as “Ireland’s university of Enterprise,” Dublin City University’s research and educational philosophy is very much informed by the institution’s strong partnerships and collaborations with the private sector. Professor Brian MacCraith discusses the institutions’ unique approach to academic-private collaborations and some of the initiatives currently underway in the life science…

Health For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He details how the organization has been able to assemble a growing number of powerful allies behind this cause, and points…

Health Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of the National Academy of Medicine and rector at UNAM (National Autonomous University of Mexico), the largest university in Latin America.…

Healthcare Senator Salvador Brito, President of the Health Commission at the Mexican Senate, talks about increasing access to quality healthcare services among the most vulnerable groups in Mexican society, improving and developing life-changing prevention policies, tackling corruption, and investing in health to ensure the country doesn’t compromise its growth perspective. What…

Health In the year of Gen Suisse’s 25th anniversary, CEO Daniela Suter talks supporting dialogue between scientists and politicians on life sciences in Switzerland, educating the general population, the attractiveness of the Swiss community for scientists, and her goals for the future. Could you give our international viewers an overview of…

Pharma Reckitt Benckiser’s General Manager for the CEE region, Lajos Magyari, discusses the strength of the company’s current portfolio, the importance of innovation and the success factors he focuses on to drive growth in the region. He outlines the company’s vision for 2020 and the significance of the health category segment.…

Hungary Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable system.   According to the OECD, life expectancy at birth in Hungary was 75.6 years in 2014, well below the…

Healthcare In part two of a two-part interview (read part one here), Mikel Arriola of the IMSS discusses the strategic roadmap IMSS will follow under his tenure with regards to innovation access and chronic disease prevention, as well as his approach to the upcoming implementation of exchanges of services among the…

Healthcare In part one of a two-part interview (read part two here), Mikel Arriola, the recently appointed general director of IMSS (Mexican Social Security Institute), which provides health-related services to more than 70 million beneficiaries, reveals his fundamental priorities to both secure IMSS’ financial sustainability and improve the quality of services…

Pharma Digitalization, a hot topic throughout the healthcare and life sciences industry, is having a major effect in Italy through more personalized home care for patients, allowing the government to cut costs, and enabling greater public access to innovative medical technologies. Telemedicine, a key differentiator in tender processes, is not yet used…

Pharma Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative diseases, and her expectations of fostering a heightened research-based relationship with the pharmaceutical industry. What have been some of the…